Cargando…
Mirincamycin, an old candidate for malaria combination treatment and prophylaxis in the 21st century: in vitro interaction profiles with potential partner drugs in continuous culture and field isolates
BACKGROUND: Spreading resistance of Plasmodium falciparum to existing drugs calls for the search for novel anti-malarial drugs and combinations for the treatment of falciparum malaria. METHODS: In vitro and ex vivo investigations were conducted with fresh P. falciparum field isolates and culture-ada...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059879/ https://www.ncbi.nlm.nih.gov/pubmed/24916383 http://dx.doi.org/10.1186/1475-2875-13-228 |
_version_ | 1782321289135915008 |
---|---|
author | Starzengruber, Peter Fuehrer, Hans-Peter Swoboda, Paul Ganesh, Deepa Haque, Rashidul Khan, Wasif A Graninger, Wolfgang Noedl, Harald |
author_facet | Starzengruber, Peter Fuehrer, Hans-Peter Swoboda, Paul Ganesh, Deepa Haque, Rashidul Khan, Wasif A Graninger, Wolfgang Noedl, Harald |
author_sort | Starzengruber, Peter |
collection | PubMed |
description | BACKGROUND: Spreading resistance of Plasmodium falciparum to existing drugs calls for the search for novel anti-malarial drugs and combinations for the treatment of falciparum malaria. METHODS: In vitro and ex vivo investigations were conducted with fresh P. falciparum field isolates and culture-adapted P. falciparum clones to evaluate the anti-malarial potential of mirincamycin, a lincosamide, alone and in combination with tafenoquine (TQ), dihydroartemisinin (DHA), and chloroquine (CQ). All samples were tested in a histidine-rich protein 2 (HRP2) drug susceptibility assay. RESULTS: Interaction analysis showed additive to synergistic interaction profiles with these potential partner drugs, with an overall geometric mean fractional inhibitory concentration at 50% inhibition (FIC(50)) of 0.78, 0.80 and 0.80 for mirincamycin with TQ, DHA, and CQ, respectively. Antagonism was not found in any of the tested field isolates or clones. The strongest tendency toward synergy (i.e. the lowest FIC) was seen with a combination ratio of 1:0.27 to 1:7.2 (mean 1:2.7) for the combination with tafenoquine. The optimal combination ratios for DHA and CQ were 1:444.4 to 1:36,000 (mean 1:10,755.5) and 1:2.7 to 1:216 (mean 1:64.5), respectively. No evidence of an activity correlation (i.e. potential cross-resistance) with DHA, mefloquine, quinine or chloroquine was seen whereas a significant correlation with the activity of clindamycin and azithromycin was detected. CONCLUSIONS: Mirincamycin combinations may be promising candidates for further clinical investigations in the therapy and prophylaxis of multidrug-resistant falciparum malaria or in combination with 4 or 8-aminoquinolines for the treatment and relapse prevention of vivax malaria. |
format | Online Article Text |
id | pubmed-4059879 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40598792014-06-18 Mirincamycin, an old candidate for malaria combination treatment and prophylaxis in the 21st century: in vitro interaction profiles with potential partner drugs in continuous culture and field isolates Starzengruber, Peter Fuehrer, Hans-Peter Swoboda, Paul Ganesh, Deepa Haque, Rashidul Khan, Wasif A Graninger, Wolfgang Noedl, Harald Malar J Research BACKGROUND: Spreading resistance of Plasmodium falciparum to existing drugs calls for the search for novel anti-malarial drugs and combinations for the treatment of falciparum malaria. METHODS: In vitro and ex vivo investigations were conducted with fresh P. falciparum field isolates and culture-adapted P. falciparum clones to evaluate the anti-malarial potential of mirincamycin, a lincosamide, alone and in combination with tafenoquine (TQ), dihydroartemisinin (DHA), and chloroquine (CQ). All samples were tested in a histidine-rich protein 2 (HRP2) drug susceptibility assay. RESULTS: Interaction analysis showed additive to synergistic interaction profiles with these potential partner drugs, with an overall geometric mean fractional inhibitory concentration at 50% inhibition (FIC(50)) of 0.78, 0.80 and 0.80 for mirincamycin with TQ, DHA, and CQ, respectively. Antagonism was not found in any of the tested field isolates or clones. The strongest tendency toward synergy (i.e. the lowest FIC) was seen with a combination ratio of 1:0.27 to 1:7.2 (mean 1:2.7) for the combination with tafenoquine. The optimal combination ratios for DHA and CQ were 1:444.4 to 1:36,000 (mean 1:10,755.5) and 1:2.7 to 1:216 (mean 1:64.5), respectively. No evidence of an activity correlation (i.e. potential cross-resistance) with DHA, mefloquine, quinine or chloroquine was seen whereas a significant correlation with the activity of clindamycin and azithromycin was detected. CONCLUSIONS: Mirincamycin combinations may be promising candidates for further clinical investigations in the therapy and prophylaxis of multidrug-resistant falciparum malaria or in combination with 4 or 8-aminoquinolines for the treatment and relapse prevention of vivax malaria. BioMed Central 2014-06-10 /pmc/articles/PMC4059879/ /pubmed/24916383 http://dx.doi.org/10.1186/1475-2875-13-228 Text en Copyright © 2014 Starzengruber et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Starzengruber, Peter Fuehrer, Hans-Peter Swoboda, Paul Ganesh, Deepa Haque, Rashidul Khan, Wasif A Graninger, Wolfgang Noedl, Harald Mirincamycin, an old candidate for malaria combination treatment and prophylaxis in the 21st century: in vitro interaction profiles with potential partner drugs in continuous culture and field isolates |
title | Mirincamycin, an old candidate for malaria combination treatment and prophylaxis in the 21st century: in vitro interaction profiles with potential partner drugs in continuous culture and field isolates |
title_full | Mirincamycin, an old candidate for malaria combination treatment and prophylaxis in the 21st century: in vitro interaction profiles with potential partner drugs in continuous culture and field isolates |
title_fullStr | Mirincamycin, an old candidate for malaria combination treatment and prophylaxis in the 21st century: in vitro interaction profiles with potential partner drugs in continuous culture and field isolates |
title_full_unstemmed | Mirincamycin, an old candidate for malaria combination treatment and prophylaxis in the 21st century: in vitro interaction profiles with potential partner drugs in continuous culture and field isolates |
title_short | Mirincamycin, an old candidate for malaria combination treatment and prophylaxis in the 21st century: in vitro interaction profiles with potential partner drugs in continuous culture and field isolates |
title_sort | mirincamycin, an old candidate for malaria combination treatment and prophylaxis in the 21st century: in vitro interaction profiles with potential partner drugs in continuous culture and field isolates |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059879/ https://www.ncbi.nlm.nih.gov/pubmed/24916383 http://dx.doi.org/10.1186/1475-2875-13-228 |
work_keys_str_mv | AT starzengruberpeter mirincamycinanoldcandidateformalariacombinationtreatmentandprophylaxisinthe21stcenturyinvitrointeractionprofileswithpotentialpartnerdrugsincontinuouscultureandfieldisolates AT fuehrerhanspeter mirincamycinanoldcandidateformalariacombinationtreatmentandprophylaxisinthe21stcenturyinvitrointeractionprofileswithpotentialpartnerdrugsincontinuouscultureandfieldisolates AT swobodapaul mirincamycinanoldcandidateformalariacombinationtreatmentandprophylaxisinthe21stcenturyinvitrointeractionprofileswithpotentialpartnerdrugsincontinuouscultureandfieldisolates AT ganeshdeepa mirincamycinanoldcandidateformalariacombinationtreatmentandprophylaxisinthe21stcenturyinvitrointeractionprofileswithpotentialpartnerdrugsincontinuouscultureandfieldisolates AT haquerashidul mirincamycinanoldcandidateformalariacombinationtreatmentandprophylaxisinthe21stcenturyinvitrointeractionprofileswithpotentialpartnerdrugsincontinuouscultureandfieldisolates AT khanwasifa mirincamycinanoldcandidateformalariacombinationtreatmentandprophylaxisinthe21stcenturyinvitrointeractionprofileswithpotentialpartnerdrugsincontinuouscultureandfieldisolates AT graningerwolfgang mirincamycinanoldcandidateformalariacombinationtreatmentandprophylaxisinthe21stcenturyinvitrointeractionprofileswithpotentialpartnerdrugsincontinuouscultureandfieldisolates AT noedlharald mirincamycinanoldcandidateformalariacombinationtreatmentandprophylaxisinthe21stcenturyinvitrointeractionprofileswithpotentialpartnerdrugsincontinuouscultureandfieldisolates |